Clinical trials: Open-Angle Glaucoma or Ocular Hypertension
Ocular Hypertension, Primary Open Angle Glaucoma
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma
This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.
- Trial name
- RENOIR (NCT07617532)
- Testing
- Product DNN.31.19.026, COSOPT®
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Open-Angle Glaucoma, Ocular Hypertension
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This study compares the efficacy and tolerability/comfort of brimonidine/timolol and dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00822081
- Testing
- brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination, dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination, brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- Bp Consulting, Inc
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02247804
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 106 sites in United States, Australia and 12 more
- Volunteers
- 594 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Primary Open Angle Glaucoma (POAG)
Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.
- Trial name
- NCT01252849
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Ocular Hypertension
A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate safety and the ocular hypotensive effect of STN1012600 ophthalmic solution 0.002% alone or in combination with Timolol ophthalmic solution 0.5% for 52 weeks in subjects with open angle glaucoma or ocular hypertension.
- Trial name
- NCT05503901
- Testing
- STN1012600 ophthalmic solution 0.002%, STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
- Where
- 18 sites in Japan
- Volunteers
- 131 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open-angle Glaucoma, Ocular Hypertension
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Eligible patients will be randomized in a 1.1 ratio to receive Travoprost 0.004%/timolol 0.5% once daily or Latanoprost 0.005%/Timolol 0.5% once a day for 8 Weeks.
- Trial name
- NCT00872651
- Testing
- Travoprost 0.004%/Timolol 0.5%, Latanoprost 0.005% / Timolol 0.5%
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the comfort of Travatan Z in one eye and Xalatan in the opposite eye in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00527592
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07168902
- Testing
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- Bausch & Lomb Incorporated
Healthy Volunteers
Bimatoprost Ocular Insert Pharmacokinetic Study
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02444767
- Testing
- 13mg Bimatoprost Ocular Insert
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069719
- Testing
- Glaucoma therapy
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of Xalatan in Patients
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
- Trial name
- A6111128 (NCT00950690)
- Testing
- Xalatan 0.005% eye drops
- Where
- 3 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,289 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open Angle, Ocular Hypertension
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
- Trial name
- NCT00804648
- Testing
- Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vistakon Pharmaceuticals
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Dry Eye Disease
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
The purpose of this study is to determine if there is a difference in the ocular signs and symptoms of subjects' eyes using Xalatan® 0.005% versus Travatan Z® 0.004% based on the outcome of subject assessment and clinical…
- Trial name
- NCT00799682
- Testing
- Xalatan, Travatan Z
- Where
- 5 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Long Island